12 completed, 7 terminated, 5 active not recruiting, 3 withdrawn. 20 Phase 2, 15 Phase 1.
Follow vistusertib: new trials by email Literature Review of vistusertib trials Research Report on vistusertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 528 | 2017-12-18 | 2025-10-27 |
| Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas AZD2014 - Meningioma | Phase 2 | Active not recruiting | Massachusetts General Hospital | 28 | 2017-10-17 | 2022-10-18 |
| Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification vistusertib (AZD2014) - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 4 | 2017-08-02 | 2018-09-20 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy AZD2014 - Stomach Neoplasms | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy AZD2014 - Cancer of Stomach | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer AZD4547, MEDI4736, Olaparib - Muscle Invasive Bladder Cancer | Phase 1 | Active not recruiting | AstraZeneca | 117 | 2016-12-28 | 2026-10-01 |
| mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme AZD2014 - Glioblastoma Multiforme | Phase 1 | Completed | Canadian Cancer Trials Group | 15 | 2016-12-22 | 2023-08-04 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma AZD2014, Ibrutinib - Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | AstraZeneca | 2016-06-01 | 2016-09-15 | |
| Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma | Phase 1 / Phase 2 | Unknown | Centre Leon Berard | 72 | 2016-04-01 | 2024-02-13 |
| Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer AZD2014, Palbociclib, Fulvestrant - Advanced and Metastatic Breast Cancer | Phase 1 | Completed | AstraZeneca | 54 | 2015-12-07 | 2024-06-06 |
| An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma AZD 2014, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Birmingham | 36 | 2015-10-01 | 2020-11-05 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 118 | 2015-06-01 | 2020-02-25 |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer AZD4547, Vistusertib, Palbociclib - Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell | Phase 2 | Completed | University of Birmingham | 423 | 2015-05-13 | 2026-04-28 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies AZD2014 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 28 | 2015-03-17 | 2024-12-17 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Meningioma (2) · Recurrence (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Disease (1)
AstraZeneca (7) · Samsung Medical Center (6) · Queen Mary University of London (3) · Massachusetts General Hospital (2) · UNICANCER (2) · University of Birmingham (2) · Acerta Pharma BV (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Royal Marsden NHS Foundation Trust (1)
United Kingdom (12) · United States (9) · South Korea (8) · France (7) · Spain (4) · Canada (3) · Germany (2) · Austria (1) · Denmark (1) · Georgia (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Anja Wiliams (1) · Birgit Geoerger, MD (1) · Christine L Hann (1) · Dr. Udai Banerji (1) · Elisabeth Oelmann (1) · Gary W Middleton (1) · Graham Collins, MBBS DPhil (1) · Hendrik-Tobias Arkenau, MD, PhD (1) · Ian W Flinn, MD, PhD (1) · Jeeyun Lee, Md,PhD (1) · John Heymach, M.D, Ph.D (1)
PMID 26410619, PMID 30016392, PMID 31465093, PMID 31538815, PMID 31707687, PMID 32067679, PMID 32203306, PMID 32379297, PMID 32669708, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 38351187, PMID 39998620, PMID 40069402, PMID 41838385, PMID 42686334
2014 (3), 2015 (2), 2009 (1), 2016 (1), 2017 (1), 2023 (1), P50CA083639 (1), R01CA201130 (1), UM1CA186691 (1)